Early detection and innovative therapies are crucial for managing rare blood disorders like VITT, ITP, and hemophilia. Marstacimab's approval offers a new subcutaneous treatment option for hemophilia ...
LINCOLN, R.I. (WJAR) — A Lincoln High School senior isn't letting a major health issue get in the way of his love for football. Last Friday night, Mitchell Mertha led the charge for the Lions game ...
SAN DIEGO -- Treatment with eltrombopag (Promacta) for pediatric patients with newly diagnosed immune thrombocytopenia (ITP) led to a significantly higher rate of durable platelet response compared ...
Novel treatment targets BTK through multi-immune modulation to help address root causes of ITP Approval based on LUNA 3 phase 3 study that demonstrated rapid and durable platelet response and ...
Pivotal phase 3 data show rapid and durable platelet response, reduced bleeding and need for rescue response, and improved physical fatigue and quality of life measures in patients with persistent or ...
An expert discusses how rilzabrutinib’s covalent reversible binding mechanism provides a favorable safety profile with only manageable grade 1 to 2 toxicities and no cardiovascular or bleeding ...
About half of people with ITP say the condition affects their emotional and psychological health, and about one-third of them say it causes them to feel self-conscious about their appearance. Moreover ...
Recommendation based on LUNA 3 phase 3 study demonstrating rapid and durable platelet response and significant improvements in bleeding, quality of life measures, and other ITP symptoms If approved, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback